Show simple item record

dc.contributor.authorLi, Chuwen
dc.contributor.authorChen, Tongkai
dc.contributor.authorZhou, Hefeng
dc.contributor.authorFeng, Yu
dc.contributor.authorHoi, Maggie PM
dc.contributor.authorMa, Dan
dc.contributor.authorZhao, Chao
dc.contributor.authorZheng, Ying
dc.contributor.authorLee, Simon MY
dc.date.accessioned2018-10-03T04:44:12Z
dc.date.available2018-10-03T04:44:12Z
dc.date.issued2018
dc.identifier.issn1663-9812
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/283050
dc.description.abstractMicroglia-mediated neuroinflammatory responses are inevitable and important pathological processes in several kinds of disorder of the central nervous system (CNS). Therefore, alleviating activated microglia-induced inflammatory process might be a valuable therapeutic approach to neuroinflammation-related diseases. In the present study, we investigated BHDPC, a novel neuroprotectant discovered in our previous study that had anti-inflammatory effects under neuroinflammatory conditions. First, we found that BHDPC could inhibit neuroinflammatory responses and promote microglial M2 phenotype polarization in both lipopolysaccharide (LPS)-activated BV-2 microglia l cells. Furthermore, BHDPC provided protective actions against neuroinflammation-induced neurotoxicity in HT22 mouse hippocampal cells co-cultured with activated BV-2 microglia. Further experiments demonstrated that BHDPC could suppress LPS-induced activation of transcription factor nuclear factor kappa B (NF-κB) via interfering with the degradation of the inhibitor of kappa B (IκB) and phosphorylation of IκB, the IκB kinase (IKK). Moreover, we also found that BHDPC could induce phosphorylation of cAMP-dependent protein kinase A (PKA) and cAMP-response element-binding protein (CREB) in BV-2 microglial cells. Also, using the PKA-specific inhibitor, we found that BHDPC-induced CREB phosphorylation was dependent on PKA, which also contributed to BHDPC-mediated anti-inflammation and neuroprotection.
dc.format.mediumElectronic-eCollection
dc.languageeng
dc.publisherFrontiers Media SA
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleBHDPC Is a Novel Neuroprotectant That Provides Anti-neuroinflammatory and Neuroprotective Effects by Inactivating NF-κB and Activating PKA/CREB.
dc.typeArticle
prism.publicationDate2018
prism.publicationNameFront Pharmacol
prism.startingPage614
prism.volume9
dc.identifier.doi10.17863/CAM.30413
dcterms.dateAccepted2018-05-22
rioxxterms.versionofrecord10.3389/fphar.2018.00614
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-01
dc.contributor.orcidZhao, Chao [0000-0003-1144-1621]
dc.identifier.eissn1663-9812
rioxxterms.typeJournal Article/Review
cam.issuedOnline2018-06-25


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International